⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6064521 | 0.84 | — | — | |
| SCHEMBL29085384 | 0.75 | CA1 (0.41) | — | |
| SCHEMBL4119295 | 0.71 | — | — | |
| SCHEMBL962066 | 0.71 | — | — | |
| SCHEMBL123971 | 0.71 | — | — | |
| SCHEMBL24596160 | 0.70 | CRBN (0.38) | — | |
| SCHEMBL31149076 | 0.69 | — | — | |
| SCHEMBL7842855 | 0.69 | — | — | |
| Succinimide SCHEMBL27636426 | 0.68 | — | — | |
| Succinimide SCHEMBL938031 | 0.67 | CRBN (0.61) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057452-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | CATYLIX, INC. (US) | 2015-02-26 | — | — | US | claimed |
| WO-2024020221-A1 | MODULATORS OF TYK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230372496-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116723839-A | Tricyclic heterobifunctional compounds for degrading target proteins | C4医药公司 | 2023-09-08 | — | — | CN | disclosed |
| EP-4228625-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4228624-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 Therapeutics, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116457339-A | Tricyclic compounds degrading novel substrates for medical treatment | C4医药公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-109071520-B | Microbicidal oxadiazole derivatives | 先正达参股股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2022081927-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20150057452-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | CATYLIX, INC. (US) | 2015-02-26 | — | — | US | disclosed |
| US-6627627-B2 | Useful as psychotherapeutic agents | PFIZER INC. | 2003-09-30 | — | — | US | disclosed |